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Summary. Degeneration of nigrostriatal dopaminergic 
neurons is the primary histopathological feature of Par- 
kinson's disease. The neurotoxin MPTP (1-methyl-4- 
phenyl-l,2,3,6-tetrahydropyridine) induces a neurological 
syndrome in man and non-human primates very similar 
to idiopathic Parkinson's disease by selectively destroying 
dopaminergic nigrostriatal neurons. This gives rise to the 
hypothesis that Parkinson's disease may be caused by en- 
dogenous or environmental toxins. Endogenous excitato- 
ry amino acids (EAAs) such as L-glutamate could be in- 
volved in neurodegenerative disorders including Parkin- 
son's disease. We report in this study that the competitive 
NMDA antagonist CPP (3-((_+)-2-carboxypiperazin-4- 
yl)-propyl-l-phosphonic a id) protects nigral tyrosine 
hydroxylase (TH) positive neurons from degeneration i - 
duced by systemic treatment with MPTP in common 
marmosets. This indicates that EAAs are involved in the 
pathophysiological cascade of MPTP-induced neuronal 
cell death and that EAA antagonists may offer a 
neuroprotective therapy for Parkinson's disease. 
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Introduction 
Administration of MPTP to man or non-human primates 
(Davis et al. 1979; Langston et al. 1983; Burns et al. 1983) 
including common marmosets (Jenner et al. 1984) induc- 
es a selective destruction of dopaminergic nigrostriatal 
neurons associated with a substantial decrease in dopa- 
mine content of the caudate nucleus and putamen. 
MPTP is converted by monoamine oxidase type B (MAO- 
B) into the dihydropyridinium species (MPDP ÷) which 
is converted non-enzymatically into the neurotoxic 
l-methyl-4-phenylpyridinium on (MPP ÷; Castagnoli et 
al. 1985). The latter compound is accumulated in- 
traneuronally by the high affinity dopamine uptake carri- 
er and temporarily stored in a releasable pool (Javitch et 
al. 1985; Schinelli et al. 1988). MPP + is taken up in- 
traneuronally by a mitochondrial carrier and inhibits 
complex I of the mitochondrial respiratory chain 
(Nicklas et al. 1985). EAAs such as L-glutamate or L-as- 
partate are transmitters in the mammalian central ner- 
vous system (Fonnum 1984) and have been claimed to be 
involved in neurodegenerative disorders including Parkin- 
son's disease (Olney 1989). This assumption is based on 
the observation that L-glutamate itself (Olney 1969) and 
compounds activating major glutamate receptor subtypes 
such as N-methyl-D-aspartate (NMDA, kainate, quis- 
qualate (QUIS) or a-amino-3-hydroxy-5-methyl-4-iso- 
xazolepropionate (AMPA) have neurotoxic properties 
and can produce xcitotoxic lesions reminiscent of human 
neurodegenerative disorders. Several lines of evidence in- 
dicate the involvement of EAAs such as glutamate in the 
neuropathological cascade of MPTP/MPP+-induced 
cell death. MPP + induces in rats a release of glutamate 
and aspartate (Carboni et al. 1990) as well as of dopa- 
mine and lactate when delivered through a dialysis probe 
to the brain (Rollema et al. 1988). Furthermore, we have 
shown that the neurotoxic effects of MPP ÷ injected fo- 
cally into the substantia nigra of rats are prevented by sys- 
temic treatment with non-competitive and competitive 
antagonists of NMDA receptors such as dizocilpine 
(MK-801) or CPP, respectively (Turski et al. 1991). Focal 
administration of MPP + to the brain results in high lo- 
cal concentrations which could possibly produce 
unspecific toxic effects (Harik et al. 1987). The present 
study was performed in order to test the hypothesis that 
EAAs are involved in the mediation of MPTP/MPP +- 
induced neurotoxicity following systemic administration 
of the neurotoxin. Since rats are not sensitive to MPTP, 
the effect of MPTP alone and in combination with the 
competitive NMDA-antagonist CPP was tested in com- 
mon marmosets. At post mortem the monoamine and 
metabolite content in the putamen was measured and a 
quantitative histological analysis of TH positive neurons 
in the substantia nigra pars compacta was performed. 
Materials and methods 
Animals and drugs. Fourteen male and 2 female common marmosets 
(Callithrixjacchus), weighing 280-420 g, aged 5 - 15 years and housed 
under standard conditions at a temperature of 27 o (_+ 1 °C), 50°7o rela- 
tive humidity and a 12 h light-dark cycle (light on from 6.00-18.00 h) 
were allocated to four age-matched groups. 
The following compounds were employed: CPP (3-((_+)-2-carboxy- 
piperazin-4-yl)-propyl-l-phosphonic acid, Research Biochemicals, 
USA), MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine h drochlo- 
ride; Schering AG) dissolved in sterile physiological saline. All solutions 
were prepared immediately before administration a d injected in a vol- 
ume of 1 ml/kg body weight. All dosages refer to the free base. 
Groups of four animals were treated with either vehicle (A, B) or 
CPP intraperitoneally (25mg/kg i.p., B, D) 30 min prior to the subcuta- 
neous administration f MPTP (6 mg/kg s.c., C, D) or vehicle (A, B) 
and subsequently with the same dose of CPP (B, D) or vehicle (A, C) 
at 4-hourly intervals for up to 44 h (see Table 1). Forty-eight hours after 
administration f MPTP or vehicle the animals were sacrificed by an 
overdose of phenobarbital and the brains quickly removed and divided 
by a coronal section at the level of the hypophysis. From the rostral por- 
tion the putamen was dissected on ice and the caudal part was used for 
subsequent immunohistochemistry. All samples were immediately 
transferred into isopentane (-80°C) and stored at -70°C until 
histological or biochemical nalysis. The MPTP dose (6 mg/kg s.c.) was 
calculated on the basis of previous experiments in this monkey species 
(LOschmann et al. 1989) and represents the maximum single dose toler- 
ated by animals aged over 10 years. The CPP dose and the treatment 
intervals were deduced from a pilot experiment in C57 black mice (data 
not shown). All animal experiments were carried out in accordance with 
the recommendations of the Declaration of Helsinki and the animal 
welfare guidelines and laws of Germany. 
Determination of biogenic amines. Biogenic amines and metabolites 
were determined using an HPLC method escribed earlier (Sofic i986). 
Frozen tissue samples were weighed and homogenized in 10 volumes of 
0.4 N perchloric acid containing EDTA and NazS205 and centrifuged 
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at 12000g, 4°C for 15min. Analysis of biogenic amines and 
metabolites was performed in supernatants u ing high performance li- 
quid chromatography (HPLC) with coulometric detection for determi- 
nation of noradrenaline and dopamine (ESA system 5700 and ESA 
coulochem detector, Model 5100 A). Separation of amines was per- 
formed on a C18 column (Nucleosil 120-5), the mobile phase consisted 
of 0.05 M sodium phosphate/sodium acetate buffer, pH 3.0, containing 
sodium dodecylsulphate and acetonitrile in deionized water (Merck, 
Lichrosolv). Quantification was performed with dihydrobenzylamide as 
internal standard. Serotonin, 5-hydroxyindol acetic acid, 3,4-dihydroxy- 
phenylacetic a id and homovanillic acid were measured using an HPLC 
system (Millipore Waters 460) with electrochemical detection on RP-18 
Bondapack columns. The mobile phase consisted of a 0.1 M sodium ac- 
etate/acetic a id buffer, pH 4.5, with 5°70 methanol and 1 mmol EDTA. 
Tyrosine hydroxylase (TH) immunohistochemistry. Tyrosine hydrox- 
ylase immunohistochemistry wasperformed in serial 25 mm coronal 
sections of frozen brains through the substantia nigra at -20 °C using 
a cryostat (Leitz 1720 digital). Sections were mounted on gelatine-coat- 
ed slides, allowed to dry for 90 s and transferred into fixative (4% 
paraformaldehyde, 10% saturated picric acid, 2% sucrose in 0.1 M 
sodiumphosphate buffer, SPB) for 45 min. Following fixation and rins- 
ing (5 min 0.I M SPB twice) peroxidase activity was removed by brief 
(40 s) exposure to hydrogen peroxide (0.1°70 H202 in 0.1 M SPB). Slides 
were rinsed again (5 min 0.1 M SPB twice) and incubated for 30 min 
with normal goat serum (NGS 10% in 0.1 M SPB containing 0.3% Tri- 
ton-X-100, SIGMA) and exposed overnight to the primary antibody 
(1:5000 monoclonal mouse anti-tyrosin hydroxylase, INCSTAR, 2% 
NGS, 0.3% Triton-X-100 in 0.1 M SPB) at 5 °C. After rinsing (5 rain 
0.1 M SPB twice) slides were incubated for 1 h (5 °C) with the secondary 
antibody (1 : 200 biotinylated goat anti-mouse IgG, SIGMA, 2% NGS, 
0.3°70 Triton-X-100 in 0.1 M SPB), rinsed twice and incubated for 1 h 
(5 °C) with ABC (1 : 200 avidin-biotin peroxidase, VECTOR, 2% NGS 
in 0.1 M SPB) and rinsed twice. The reaction product was visualized us- 
ing diaminobenzidine (50mg/100 ml, SIGMA, 0.015% hydrogenperox- 
ide in 0.1 M SPB) for 30-60 min and intensified with osmium tetroxide 
(0.005% in dest. water), if necessary. Slides were left to dry and 
coverslipped with DePeX (SERVA). 
Quantitative histology of TH-positive neurons. For morphological 
analysis brain sections were visually inspected at all rostro-caudal levels 
extending from planes A6 to A3 according to a standard stereotaxic at- 
las of marmoset brain (Stephan et al. 1980). Unilateral quantification 
of intact TH-positive neurons was performed under blind conditions by 
a single observer (M.B.) at the widest aspect of the substantia nigra pars 
compacta (SNC) at the level A4-A3.5 using a Leitz Aristoplan micro- 
scope equipped with a counting rid (Leitz no. 513740) at a magnifica- 
tion of x 100. For every SNC topographical maps of TH-positive cells 
were constructed graphically and total counts calculated for two planes 
on one side. Neurons bearing dendrites and regularly shaped somata 
were accounted to be normal. 
Statistical analysis. Statistical differences between groups in mono- 
amine levels and in the sums of the cell counts at two levels of the sub- 
stantia nigra were calculated by Kruskal-Wallis one-way analysis of vari- 
ance followed by post-hoc omparisons u ing the Mann-Whitney U-test. 
Table 1. Group characteristics and treatment schedules. The animals were treated with either vehicle (A, B) or CPP intraperitoneally (25 mg/kg i.p., 
B, D) 30 min prior to the subcutaneous administration f MPTP (6 mg/kg s.c., C, D) or vehicle (A, B) and subsequently with the same dose of CPP 
(B, D) or vehicle (A, C) at 4-hourly intervals for up to 44 h. Four hours later the animals were sacrificed by an overdose of phenobarbital 
Group (n = 4) Mean age Vehicle MPTP Vehicle CPP 
(years, SEM) (MPTP) (6 mg/kg s.c. once) (CPP) (25 mg/kg i.p. every 4 h) 
(A) Vehicle 9.75 (2.06) × × 
(B) CPP 12.00 (1.I0) × × 
(C) MPTP 9.25 (1.93) × × 
(D) MPTP + CPP 9.25 (2.02) × × 
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Results 
Behavioural observations 
Treatment with MPTP resulted in a brief period of 
behavioural stimulation lasting two hours, followed by 
sedation and hypokinesia, whereas CPP induced seda- 
tion. The stimulation caused by MPTP was less pro- 
nounced in the group of animals treated with both MPTP 
and CPP. The animals were continuously observed 
throughout the experiment; no side effects, other than se- 
dation, were observed. 
Effects upon tissue levels of biogenic amines 
In comparison to the control group, tissue concentrations 
of dopamine metabolites dihydroxyphenylacetic a id 
(DOPAC) and homovanillic acid (HVA) were decreased in
the putamen after MPTP treatment (DOPAC P = 0.043, 
HVA: P = 0.021, Kruskal-Wallis one-way analysis of vari- 
ance followed by the U-test, cf. Fig. 1). Treatment with 
CPP did not affect levels of DOPAC, HVA and dopa- 
mine. The combined treatment with MPTP and CPP re- 
sulted in reduced HVA levels (P = 0.043). Due to the vari- 
ability in tissue concentrations o significant effects upon 
dopamine concentrations were obtained. Noradrenaline, 
serotonin (5-HT) and 5-hydroxyindolacetic acid 
(5-HIAA) in the putamen were not affected by the differ- 
ent treatments (cf. Table 2). 
Effects upon TH-positive nigral neurons 
Unilateral cell counts of TH-positive neurons were per- 
formed under blind conditions at two levels of the 
substantia nigra pars compacta of each animal. Treat- 
ment with MPTP alone induced a 70% decrease of intact 
TH-positive neurons (P = 0.043, Kruskal-Wallis one-way 
• analysis of variance followed by the U-test, cf Fig. 2), 
whereas neither CPP alone nor CPP in combination with 
MPTP affected the cell numbers (P = 0.021, Kruskal- 
Fig. 1A-C.  Individual evels of dopamine (A), DOPAC (B) and HVA 
(C) the putamen (open symbols) and the median with the 25-  75 inter- 
quartil ranges (bars) for common marmosets treated with vehicle 
(VEH), MPTP (6 mg/kg s.c.), CPP (25 mg/kg i.p. at 4-hourly intervals 
for up to 44 h) alone or in combination with MPTP (MPTP+CPP). 
Levels were determined in tissue homogenates and are given in ng/mg 
tissue wet weight• MPTP caused a significant decrease in DOPAC (B 
*P = 0.043) and HVA (C *P = 0.021) tissue content. Combined treat- 
ment MPTP and CPP reduced HVA levels (C *P = 0.043) 
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Table 2. Biogenic amines in the putamen. Levels were determined in tissue homogenates (ng/mg tissue wet weight, median, 25-75 interquartil 
ranges in parentheses, n = 4) 
Compound Putamen 
Vehicle CPP MPTP + CPP MPTP 
Noradrenaline 0.08 (0.04 - 0.13) 0.13 (0.07 - 0.2) 0.07 (0.03 - 0.19) 0.04 (0.02 - 0.33) 
5-HT 0.25 (0.18 - 0.64) 0.28 (0.19 - 0.32) 0.27 (0.11 - 0.83) 0.79 (0.35 - 1.04) 
5-HIAA 0.49 (0.35-0.76) 0.77 (0.36-1.19) 0.56 (0.19-1.16) 0.96 (0.39-1.51) 
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Fig. 2. Intact TH-positive cells. Individual sums of substantia nigra cell 
counts obtained at two levels (open symbols) and the median with the 
25-75  interquartil ranges (bars) for common marmosets treated with 
vehicle (VEH), MPTP (6 mg/kg s.c.), CPP (25 mg/kg i.p. at 4-hourly 
intervals for up to 44h) alone or in combination with MPTP 
(MPTP + CPP). The number of  TH-positive neurons was significantly 
reduced in the MPTP group (*P = 0.043 MPTP vs control, P = 0.021 
CPP and CPP+MPTP vs MPTP; Kruskal-Wallis one-way analysis of 
variance followed by the Mann-Whitney U-test) whereas there were no 
significant differences between the vehicle-treated group and the CPP 
or CPP+MPTP groups, respectively 
Wallis one-way analysis of variance followed by the U-test 
vs MPTP, cf Fig. 2). Examples of nigral sections tained 
for TH are shown in Fig. 3. 
Discussion 
We demonstrate for the first time a protection of nigral 
neurons from MPTP-induced neurotoxicity by a com- 
petitive NMDA antagonist in a primate species. These re- 
sults are in accordance with findings obtained using the 
non-competitive NMDA antagonist MK-801 in another 
primate species (Zuddas et al. 1992). A neuroprotective 
effect has been observed at the morphological level, i.e. 
TH-positive (most likely dopaminergic) nigral cell somata 
are protected. 
Acute or subchronic treatment of common marmo- 
sets with MPTP results in a drastic decrease of dopamine 
concentrations in all dopamine-innervated brain areas 
including the putamen (Rose et al. 1989) causing 
behavioural sedation and akinesia (L6schmann et al. 
1989). The treatment schedule employed with a single 
high dose of MPTP and repeated injections of CPP has 
been chosen for two reasons. MPP ÷, formed from 
MPTP is accumulated by nerve terminals and fibers but 
not by somata (Herkenham et al. 1991) and is detectable 
for days in primate brains (Johannessen et al. 1985). In 
contrast, the half life of CPP in primates is relatively 
short as deduced from our experiments in MPTP-treated 
common marmosets (L6schmann et al. 1991). Since the 
sensitivity of common marmosets to the neurotoxic ef- 
fects of MPTP seems to be age-related, aged animals 
(5-15 years) were used in the present study. In the vehicle 
treated group dopamine concentrations in the putamen 
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were in the range of 5 ng/mg wet weight, whereas 
10 ng/mg have been reported by others (P6rez-Otafio et 
at. 1991) in juvenile (aged 1 -2  years) marmosets. The 
lower dopamine and metabolite levels in the putamen in 
our sample could be explained by differences in the dis- 
section technique but we consider an age-related decrease 
in dopamine content o be the more likely cause. A single 
dose of MPTP induced an 80°70 decrease in dopamine 
content of the putamen. The levels of the metabolites 
DOPAC and HVA were significantly reduced and those 
of the other monoamines analysed were not affected by 
MPTP-treatment. CPP when administered alone did not 
affect dopamine levels or other transmitters and metabo- 
lites. Combined treatment with MPTP plus CPP caused 
variable effects on dopamine concentrations ( ee Fig. 1). 
However, the combination of MPTP and CPP caused a 
slight reduction in DOPAC and a significant decrease in 
HVA. The reduction of metabolite concentrations could 
be related to the fact the MPP + has MAO blocking 
properties (Feuerstein et al. 1988). Taken together, these 
results indicate that CPP provided no protection against 
MPTP-induced opamine depletion in the putamen. Sub- 
sequent studies employing reater sample sizes may show 
a significant protection at the neurochemical level. 
Non-competitive NMDA antagonists such as MK-801 
or phencyclidine as well as the competitive NMDA antag- 
onist D-2-amino-5-phosphopentanoate (D-AP5) cause ir- 
reversible pathomorphological changes in the cingulate 
and retrosplenial cerebral cortex of rats when adminis- 
tered in high doses (Olney et al. 1989). CPP in a dose of 
50 mg/kg i.v. caused avacuole reaction similar to MK-801 
in rats (Olney et al. 1991). Since we used considerably 
lower doses (25 mg/kg) and a less effective route of ad- 
ministration (i.p.) it is unlikely that such effects influenc- 
ed our results. 
At the level of nigral dopaminergic cell bodies CPP 
provides complete protection to TH-positive cells from 
MPTP-induced degeneration. This effect was evident as 
late as 48 h following a single exposure to MPTP. It is 
very likely that prolonged treatment with CPP would 
have extended the period of protection. This speculation 
needs to be proven in subsequent studies. 
Although it is still an unresolved question how 
MPTP/MPP + selectively destroys dopaminergic neu- 
rons, these results upport he notion of a critical involve- 
ment of NMDA receptor-mediated events in this process. 
Due to impairment of mitochondrial respiration resulting 
in EAA release from glial and neuronal stores. The com- 
promised energy supply, induced by MPP + could result 
in a partial membrane depolarisation which in turn 
would remove the voltage-dependent Mg2+ block from 
NMDA receptor ion channels (Nowak et al. 1984). This 
would enable EAAs such as glutamate to become 
neurotoxic through persistent receptor stimulation 
(Novelli et al. 1988). The compromised energy metabo- 
lism and Ca 2+ homeostasis are further factors in the in- 
creased vulnerability of these cells. The neurotoxicity of 
MPTP to dopaminergic terminals was not prevented by 
systemic treatment with CPP since the metabolites 
DOPAC and, to a greater extent, HVA were reduced in 
the putamen. At the level of dopaminergic somata, how- 
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Fig. 3A-H.  Representative nigral sections stained forTH, Given are examples for monkeys treated with vehicle (A, B), CPP (C, D), MPTP (E, F) 
and MPTP+CPP (G, H). Bars represent 250 ~tm (left panel) and 50 ~tm (right panel) 
ever, blockade of NMDA receptors enables TH-positive 
neurons to survive. One could speculate that other pro- 
perties than NMDA antagonism of CPP account for the 
protection. Theoretically this compound could inhibit he 
binding of MPP ÷ to neuromelanin i  a similar way to 
chloroquine which protected monkeys against MPTP tox- 
icity (D'Amato et al. 1987). However, since CPP did pro- 
tect against MPP ÷ injected focally into the substantia 
nigra of albino rats which is not pigmented (Turski et al. 
1991) as well as in common marmosets having a pigment- 
ed nigra following systemic treatment with MPTP (this 
study), this is very unlikely. The discrepancy between our 
report on the neuroprotective effects of MK-801 and CPP 
following intranigral injection of MPP + in rats (Turski 
et al. 1991) and findings showing an absence of protec- 
tion of MK-801 against striatal dopamine depletion in- 
duced by systemic MPTP in mice (Sonsalla et al. 1989) 
could be explained by this observation. More recently, it 
was reported that MK-801 failed to protect TH-positive 
nigral neurons against intranigral MPP + neurotoxicity 
(Sonsalla et al. 1992). In this study however, MK-801 was 
administered for only 24 h. This short period of time may 
not have been adequate to protect nigral neurons. The re- 
sults of the present study indicate that TH-positive neu- 
rons can be protected against MPTP/MPP + neurotoxici- 
ty by the continuous presence of the NMDA antagonist 
CPP. 
MPTP induces rapid damage of nigral dopamine neu- 
rons leading to the development of parkinsonian symp- 
toms in humans and non-human primates within a short 
period of time, whereas in Parkinson's disease a slowly 
degenerative process is suggested by the chronic progres- 
sion of the disease. This difference could indicate that en- 
dogenous or environmental compounds, chemically very 
closely related to MPTP, are probably not a cause for 
Parkinson's disease. Nevertheless, the striking similarities 
between the model and the disease suggest at least some 
common etiopathological features. NMDA receptor-me- 
diated processes are potential factors in the mechanism 
underlying both Parkinson's disease and MPTP-induced 
parkinsonism. It has been shown, for example, that the 
unusual amino acid fl-N-methylamino-L-alanine, proba- 
bly responsible for the amyotrophic lateral sclerosis- 
parkinsonism-dementia complex of Guam (Spencer et al. 
1987), activates glutamate receptors. 
NMDA receptor antagonists would seem to offer a 
neuroprotective treatment for Parkinson's disease, al- 
though these results need to be confirmed in clinical trials 
employing NMDA antagonists. Such an approach could 
be particularly attractive since we have recently shown 
that the competitive NMDA antagonist CPP has syner- 
gistic effects with L-DOPA in reversing parkinsonian 
symptoms in MPTP-treated common marmosets 
(LOschmann et al. 1991). This assumption could be tested 
directly, since memantine, a compound widely used in 
Europe as an antiparkinsonian agent, displaces 
[3H]MK-801 in binding studies (Kornhuber et al. 1989) 
and has non-competitive NMDA antagonistic properties 
in functional models (Bormann 1989; Lupp et al. 1992). 
Unfortunately there are no published retrospective or 
prospective studies on the long-term effects of meman- 
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tine or other amino-adamantanes on the progression of 
Parkinson's disease. It is therefore still reasonable to 
hypothesize that NMDA antagonists could improve both 
the symptomatology and the progression of Parkinson's 
disease. 
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